Among participants with higher ALT levels, the cancer risk decreased with an increase in the new-onset age of NAFLD, and these associations were modified by age (eTable 5 in Supplement 1). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.